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ABSTRACT 
 
Serum levels of interleukin (IL)-33, IL-36 and IL-37 have been reported to be up-
regulated in various T helper (Th)1/Th17 mediated autoimmune/inflammatory diseases. 
Although IL-33 and IL-36 expression are increased in skin lesions of patients with psoriasis, 
their serum levels in such patients have not yet been adequately studied. We aimed to 
evaluate serum level of IL-33, IL-36 and IL-37 cytokines and IL-37 gene expression in 
patients with autoimmune/inflammatory disease of psoriasis and to explore their correlation 
with disease severity. Such evaluation further clarifies disease pathogenesis and may be 
utilized in clinical practice. 
47 patients with psoriasis vulgaris and 47 healthy individuals were included. Serum IL-33, 
IL-36 and IL-37 levels were measured by Elisa and gene expression of IL-37 measured by 
real time PCR in all participants. The disease activity was assessed by the psoriasis area and 
severity index (PASI). Linear Correlation between interleukin measures and PASI score was 
calculated. Also sensitivity and specificity of such measurements were determined.  
Serum IL-36 and 37 levels in patients with psoriasis vulgaris were significantly higher than 
those in healthy controls and positively correlated with disease activity (PASI score). Serum 
IL-33 levels in patients were equal to those in healthy controls but positively correlated with 
disease activity. Serum IL-36 levels were significantly higher than serum IL-33 levels. Gene 
expression of IL-37 levels in patients were higher than healthy controls but was not 
correlated with disease activity. 
Serum IL-36 and IL-37 levels are generally increased in psoriasis vulgaris and correlated 
with disease severity. Therefore, serum IL-36 and IL-37 levels may be markers of treatment 
and diagnosis of psoriasis. 
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INTRODUCTION 
 
Psoriasis is a chronic, proliferative, congenital and 
inflammatory skin disease characterized by raised, red 
scaly plaques.
1
 The disease prevalence is about 2-3% of 
the world-wide population
2
 associated with several co-
morbidities such as cardiovascular complications.
3
 
Although psoriasis develops by chronic interactions 
between hyperproliferative keratinocytes and 
infiltrating activated immune cells,
4
 its definite 
pathogenesis remains not clear. However, evidences 
have indicated that some kinds of imbalances between 
pro- and anti- inflammatory cytokines play important 
roles.
5
 For example, one study has revealed the 
association of psoriasis with different cytokines of 
tumour necrosis factor (TNF), IL-22 and IL-17.
6
 
IL-33 is known as an inflammatory member of IL-
1
7
 which is released from cells undergoing necrosis
8
 
and binds to cells containing its receptor, ST2 receptor, 
such as mast cells, eosinophils and Th2 cells.
9
 Binding 
to Th2 cells, IL-33 plays an essential role in Th2-driven 
diseases like atopic dermatitis, asthma and allergy.
9 
This activity of IL-33 could be generated by production 
of IgE from B cells and IL-4, IL-5, and IL-13 cytokines 
fromTh2 cells in which IL-33 triggers the induction of 
GATA3 and signal transducer and activator of 
transcription 5 (STAT5).
10
 
 It has been shown that IL-33 is increased in skin 
lesions of psoriatic patients
11
 and also in serum of some 
inflammatory/autoimmune diseases such as rheumatoid 
arthritis,
12
 and inflammatory bowel disease (IBD)
13
 
correlated with severity of them.
13,14
 
IL-36 is the other member of IL-1 family that is 
produced by skin keratinocytes, bronchial epithelium, 
monocyte and lymphocytes;
15
 and it mainly acts on T-
cells and dendritic cells.
16
 Conducting their 
inflammatory roles, all 3 forms of IL-36, named IL-36-
α, IL-36-ʙ and IL-36-ϒ, are agonistically able to 
activate the MAPK and JNK through IL-36R
17
 which 
targets the promotor of IL-8 and leads to secretion of 
IL-6.
18
 Elevation of IL-36 has been shown in psoriatic 
skin lesions.
6,19
 An association of IL-36 has been found 
with one form of psoriasis, generalized pustular 
psoriasis, which is more severe than psoriasis 
vulgaris.
20,21
 
IL-37, an anti-inflammatory member of IL-1 
family,
22
 is produced by peripheral blood mononuclear 
cells (PBMCs) and dendritic cells (DCs) under 
induction of several toll-like receptor (TLR) agonists 
and pro-inflammatory cytokines such as IL-1β, 
interferon (IFN)-γ, and TNF-α.23 IL-37 may play an 
important inhibitory role in the development of 
inflammatory diseases. The serum levels of IL-37 in 
plasma of rheumatoid arthritis patients were 
significantly higher than healthy controls.
24
 Psoriatic 
lesions express higher IL-37 than skin of healthy 
individuals.
25
 In addition, serum IL-37 levels and the 
expression of IL-37 mRNA in PBMCs are much higher 
in patients with ankylosing spondylitis,
26
 Graves’ 
disease
5
 and systemic lupus erythematosus
27,28
 
compared to those in healthy controls. 
Stimulation/inhibition of the innate immune system 
respond could be one of the main therapeutic strategies 
in the treatment of psoriasis in close future. From one 
point, since there are limited studies on serum level of 
IL-33, 36 and no studies on IL-37 in patients with 
psoriasis and on the other hand, the pathogenesis of 
psoriasis is ambiguous, we aimed to evaluate serum 
level of IL-33, IL-36 and IL-37 and gene expression of 
IL-37 in such patients. If the changes of such cytokines 
be significant in psoriasis, our study may confirm their 
effect on the severity of psoriasis. In addition, a 
pharmacological block or stimulation of them may be 
effective in treatment of the disease. 
 
MATERIALS AND METHODS 
 
Patients 
This case-control study was performed on 47 
psoriasis patients in remission phase. All patients were 
randomly selected from the dermatology clinic of 
Kashan’s Shahid Beheshti hospital. Exclusion criteria 
were smoking, using corticosteroid drugs and having 
other chronic inflammatory or autoimmune diseases. In 
addition, 47 healthy volunteers without a family history 
of psoriasis and other autoimmune as well as 
inflammatory diseases were enrolled as control group. 
The study protocol was conformed to the ethical 
guidelines of the 1975 Helsinki Declaration (N. 94018, 
94023). Written informed consent obtained from all 
participants. 
 
Disease Severity Measurement 
The disease activity of psoriasis was evaluated by 
the psoriasis area and severity index (PASI).It is 
divided to mild, moderate and severe categories based 
on the scores taken by the patient according to the 
surface area involvement of 4 body regions including 
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head, trunk, lower and upper limbs and their 
histo-clinical profiles of desquamation, infiltration and 
erythema.
29
 
 
Sampling and Experiments 
Serum samples were collected from peripheral 
veins. Serum levels of IL-33, IL-36, and IL-37 were 
measured using available enzyme-linked 
immunosorbent assay (ELISA) kit (My Biosource, 
USA) according to the manufacturer’s directions. Fresh 
peripheral blood mononuclear cells (PBMCs) were 
separated from 2 mL of anticoagulated blood by Ficoll-
Hypaque (Lymphodex, Inno-Train, Germany) density 
gradient centrifugation. Gene expression assay was 
conducted by real-time PCR. Total RNA was extracted 
from PBMC using High Pure RNA Isolation Kit, Cat 
No: 11828665001, Roche Applied Science, cDNA 
synthesized from the extracted RNA using Transcriptor 
First Strand cDNA Synthesis Kit, Cat No: 
04897030001, Roche Applied Science. The amount of 
IL-37 gene expression was measured through Taqman 
primer probe Comparative ΔCT method using ABI 
7300 Real-Time PCR system as previously 
described.
30β-actin housekeeping gene was used as 
endogenous control. 
 
Statistical Analysis 
The serum levels of IL-33, IL-36, and IL-37 and 
gene expression of IL-37 were analysed by independent 
t and chi-square tests. Correlations between variables 
were calculated by Pearson’s correlation coefficient. 
Simultaneous effects of various factors on such 
cytokines were analysed by multiple linear regressions 
with backward method. p<0.2 was considered as 
exclusion criterion from the model. Adjusted R 
Squared was determined as a criterion of goodness-of-
fit the model. Using ROC and Area under Curve 
(AUC), we tried to determine the specificity, 
sensitivity, positive predictive value (PPV) and 
negative predictive value (NPV) of those inflammatory 
markers in the diagnosis of psoriasis. Data were 
expressed as mean ± standard deviation (SD) and 
analysed by SPSS16software (SPSS Inc, SPSS Inc., 
Chicago, USA). p<0.05 was considered statistically 
significant. 
 
RESULTS 
 
Basic and clinical characteristics of psoriasis 
patients and healthy group are presented in Table 1. 
The serum levels of IL-36(50.52±31.06 
versus34.12±20.35, p value=0.007), IL-37(49.35±19.96 
versus41.06±15.12, p value=0.027) and gene 
expression of IL-37(9.33±2.31 versus7.41±1.94,  
p value<0.001) in patients were significantly higher 
than those in controls. 
 
 
Table 1. Basic and clinical characteristic of psoriatic patients and healthy subjects being  evaluated in terms of IL-33, IL-36, 
IL-37 serum levels and gene Expression of IL-37  
 Psoriasis patients Health subjects p value 
Number of subjects 47 47 - 
Sex (Male/female) 15.32 18.29 0.517 
Age (years)(Mean±SD) 33.83±11.93 30.17±4.82 0.09 
Family history Positive 14(29.8)  
 
 
- 
 
Negative 33(70.2) 
Disease duration (years) 13.64±9.1 
Number of patients 
with different PASI 
Score (%) 
Mild (0-10) 38(80.9 %) 
Moderate(11-19) 4(8.5%) 
Severe(>19) 5(10.6%) 
BMI 25.88±3/79 25.2±3.64 0.1 
IL-33 serum level (pg/mL) 19.21±9.43 19.30±6.58 0.954 
IL-36 serum level (pg/mL) 50.52±31.06 34.12±20.35 0.007 
IL-37 serum level (pg/mL) 49.35±19.96 41.06±15.12 0.027 
IL-37 gene expression (pg/mL) 9.33±2.31 7.41±1.94 <0.001 
PASI: Psoriasis area and severity index,                                      BMI: Body mass index 
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Association of Serum Levels of IL-33, IL-36, and 
IL-37 and Gene Expression of IL-37 with Basic and 
Clinical Characteristics of Psoriatic Patients 
The psoriasis patients were divided into different 
groups according to PASI score, sex, family history, 
disease duration and age (Tables 2, 3). There was a 
significant association between IL-33 and IL-36 serum 
levels with disease severity (p<0.001) (Table 2). Also, 
the serum levels of IL-37 were significantly higher in 
patients based on disease severity (p=0.008). There was 
no significant difference between gene expressions of 
IL-37 according to PASI score in patients’ group 
(p=0.667) (Table 3). 
Correlation of Serum levels of IL-33, IL-36 and IL-
37 and Gene Expression of IL-37 with Different 
Parameters in Psoriatic Patients 
Correlation between the serum levels of IL-33, IL-
36, and IL-37 and gene expression of IL-37 with PASI, 
body mass index (BMI), age and disease duration in 
psoriatic patients showed a meaningful correlation 
between IL-33, IL-36 and IL-37 serum levels with 
PASI score. The most powerful relation was evaluated 
in the case of IL-36 serum level with PASI score 
(Table 4). 
 
 
Table 2. Values of IL-33 and IL-36 serum levels according to different varieties in psoriatic patients  
variables status IL-33 (pg/mL) p value IL-36 (pg/mL) p value 
Age <20 
20-39 
>39 
19.39±1.77 
18.96±9.13 
19.63±11.15 
0.813 29.20±22.06 
53.03±31.77 
50.10±31.22 
0.002 
Disease duration 
(years) 
0-10 
11-19 
>19 
18.29±8.64 
18.78±8.36 
22.58±13.49 
0.438 43.26±23.00 
61.10±39.45 
49.32±29.28 
0.272 
Sex Male 19.48 ± 8.04 0.920 50.54 ± 31.37 0.047 
Female 19.30 ± 8.15 38.75 ± 24.30  
Family history No 19.09±8.45 0.700 54.07±32.61 0.315 
Yes 20.27±11.82 44.04±26.44 
PASI Score (%) Mild (0-9.9) 16.03±7.13 <0.001 40.40±22.11 <0.001 
Moderate (10-19.9) 31.83±7.69 72.83±11.46 
Severe(>20) 32.60±4.63 107.53±29.13 
PASI: Psoriasis area and severity index, 
 
Table 3. Values of IL-37 serum level and its gene expression according to different variables in psoriatic patients 
variables 
IL-37 serum levels 
(pg/mL) 
p value 
IL-37 gene expression 
(pg/mL) 
p value 
Age <20 
20-39 
>39 
51.80±17.55 
47.67±20.14 
52.00±20.99 
0.217 10.00±2.00 
9.46±2.40 
8.93±2.28 
0.242 
Disease duration 
(years) 
0-10 
11-19 
>19 
45.30±17.66 
48.95±18.95 
61.31±25.32 
0.159 9.32±2.23 
9.06±2.26 
9.88±2.80 
0.958 
Sex Male 44.92 ± 17.29 0.923 8.62 ± 2.28 0.488 
Female 45.30 ± 18.37 8.27 ± 2.33  
Family history No 48.31±18.27 0.586 9.03±2.06 0.156 
Yes 51.80±23.41 10.07±2.67 
PASI Score (%) Mild (0-9.9) 45.04±16.94 0.008 9.24±2.17 0.667 
Moderate (10-19.9) 67.54±24.95 9.00±2.83 
Severe(>20) 66.74±23.53 10.20±3.27 
PASI: Psoriasis area and severity index, 
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Linear multiple regression analysis showed that the 
factors of BMI, serum levels of IL-33 and IL-36 have a 
positive effect on PASI score. Such model showed a 
mainly high goodness-of-fit (Adjusted R
2
=0.64) (Data 
not shown).Modelling the effects of serum levels of IL- 
33, IL-36 and IL-37 on psoriasis severity, we also 
found a high goodness-of-fit (Adjusted R
2
=0.623) 
(Data not shown). Furthermore, we indicated that the 
combination of serum levels of IL-36 and IL-37 show a 
proper criterion in the evaluation of psoriasis severity 
(Adjusted R
2
=0.608) (Table 5). 
Cut-off Points and Predictive Values 
Using ROC curve and AUC, we tried to determine 
the sensitivity and specificity of IL-33, IL-36 and IL-37 
serum levels and IL-37 gene expression as diagnostic 
markers of psoriasis (Figures 1 and 2, Table 6). The 
most specificity was found in the cut-off point of IL-
36=25.4, and the most sensitivity was found in the cut-
off point of IL-37 gene expression= 7.5. 
 
 
 
Table 4. Correlation between the serum levels of IL-33, IL-36, and IL-37 and gene expression of IL-37 with each other and 
different characteristics of the psoriatic patients and interleukins  
 IL-33 (p value) IL-36 (p value) IL-37 (p value) IL-37 gene expression (p value) 
PASI 0.605 (<0.001) 0.763 (<0.001) 0.482 (0.001) 0.071 (0.633) 
BMI 0.010 (0.924) 0.220 (0.033) 0.145 (0.163) 0.152 (0.144) 
Disease duration 0.231 (0.118) 0.179 (0.229) 0.342 (0.019) 0.035 (0.814) 
Age 0.060 (0.563) 0.268 (0.009) 0.137 (0.187) 0.201 (0.052) 
IL-33 serum level 1 0.34 (0.001) 0.30 (0.003) -0.15 (0.14) 
IL-36 serum level 0.34 (0.001) 1 0.25 (0.015) 0.03 (0.74) 
IL-37 serum level 0.30 (0.003) 0.25 (0.01) 1 0.16 (0.12) 
IL-37 gene   expression -0.15 (0.14) 0.03 (0.74) 0.16 (0.12) 1 
PASI: Psoriasis area and severity index, 
BMI:Body mass index  
 
 
Table 5. Coefficients multiple linear regression model for evaluation of psoriasis severity by PASI score 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients t Sig. Adjusted R square 
B Std. Error Beta 
2 
(Constant) -8.626 2.507 ---- -3.441 .001 0.608 
IL_36 .213 0.031 0.678 6.787 .000 
IL_37 0.109 0.049 0.222 2.223 .031 
a. Dependent Variable: PASI score 
 
 
Table 6. Sensitivity, specificity and predicting values of IL-33, IL-36 and 37 serum levels and IL-37 gene expression in 
psoriasis diagnosis 
Variable Cut point 
Sensitivity 
(%) 
Specificit
y (%) 
Positive predicting 
value (%) 
Negative predicting 
value (%) 
Area under 
curve 
IL-33 serum level 30.27 19.1 93.6 75 53.7 0.471 
IL-36 serum level 25.40 83 42.6 59.1 71.4 0.665 
IL-37 serum level 53.5 42.6 85.1 74.1 59.7 0.609 
IL-37 Gene expression 7.5 85.1 55.3 65.6 78.8 0.736 
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Figure 1. Sensitivity and specificity of IL-33 and IL-36 in psoriasis diagnosis 
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Figure 2. Sensitivity and specificity of IL-37 and gene expression of IL-37 in psoriasis diagnosis 
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DISCUSSION 
 
IL-36 and IL-37 serum levels and IL-37 gene 
expression of PBMCs were significantly higher in our 
psoriatic patients than those in healthy controls. More 
importantly, our results showed a positive correlation 
between the serum levels of IL-33, 36 and 37 with 
disease severity. Previous studies have reported 
increased IL-33 levels in psoriatic lesion
11,31,32
 as well 
as serum of psoriatic patients.
33
 IL-33 is a known 
inducer of inflammatory cytokine of IL-6 in mast cells, 
and the number of IL-33
+
 cells is increased 
significantly in Köbner positive dermal skin.
34
 Such 
lesional elevation has been also showed in the case of 
IL-36.
6,35
 
Considering inflammatory/anti-inflammatory 
effects of IL-36/IL-37, we may conclude involvement 
of such cytokines in the modification of inflammation 
in psoriasis. A growing number of studies have 
indicated that IL-37 inhibits inflammatory reactions in 
autoimmune diseases in which it is commonly 
associated with disease severity.
36,37
 IL-37 can reduce 
the symptoms of colitis
25
 and psoriasis
34
 by inhibiting 
the expression of inflammatory cytokines such as IL-
33. Increased serum level of IL-37 in our psoriatic 
patients and also increased its gene expression in 
systemic lupus erythematosus patients
28
 correlated to 
disease severity
27
 should be considered as a 
compensatory response not yet enough to alleviate the 
inflammatory state of the disease. Such correlation may 
confirm that such compensation starts at intracellular 
level and non-interferingly continues at serum level. 
Actually, since serum levels of anti-inflammatory 
marker of IL-37 in our study showed positive 
correlations with psoriasis severity, it seems that such 
marker may counterpart inflammatory effects of IL-33 
as well as IL-36, and in this way it could improve the 
skin function of the patients. Yanmei et al 
demonstrated significantly lower IL-37 serum levels in 
IBD patients than those in healthy controls. However, 
IL-37 gene expression was higher in those patients and 
its serum levels were inversely correlated with disease 
severity.
38
 
Since there are some challenges accompanying 
current assessment tools of psoriasis diagnosis, we 
designed different models containing different 
combinations of the mentioned inflammatory markers 
in the diagnosis of psoriasis. Having compared 
different models, we found that each lonely marker of 
IL-33, IL-36, IL-37 serum level as well as IL-37 gene 
expression shows a low strength in the diagnosis of 
psoriasis. It means that we need to apply statistical 
methods such as discriminant analysis,generalized 
linear model or latent profile analysis to evaluate the 
combinatory effects of such measurements in the 
diagnosis of psoriasis. Moreover, assessing the effect of 
any variable on severity of psoriasis, we should use 
multivariate ordinal logistic. Such analyses will be 
explained in our next article. 
However, we indicated that the combination of 
serum levels of IL-36 and IL-37 shows a proper 
criterion in the evaluation of psoriasis severity by PASI 
score, especially considering that such combination 
lacks evaluating the IL-33 serum level and IL-37 gene 
expression whose measurements are more expensive 
and are not done routinely in most laboratories. 
The limitation of our study was that firstly, we did 
not monitor the changes of selected cytokines 
longitudinally. This limitation allowed just a cross-
sectional analysis of cytokine profiles of only limited 
robustness. Secondly, functional assays, which provide 
further information on molecular mechanisms of such 
inflammatory and anti-inflammatory cytokines, were 
not performed. However, our study may provide deeper 
insights into the functional role of IL-1 family in the 
control of psoriasis. 
Our finding shows that serum level of IL-36 and IL-
37 and gene expression of IL-37 elevate in psoriatic 
patients. Such measurement may be a tool to assess the 
disease severity and also it may be a reflection of 
disease diagnosis. 
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